Sun Pharma's profit falls on Organon deal charge; specialty drug sales remain strong
Sun Pharma's profit falls on Organon deal charge; specialty drug sales remain strong Reuters Sun Pharma Q2 profit plunges 36% on exceptional charges despite revenue growth The Hindu Sun Pharma Q2 Results: PAT falls 36% to Rs 1,989 crore, misses estimates; revenue meets mark Zee Business How Is Sun Pharmaceutical Industries (NSE:SUNPHARMA) Balancing Innovation Spending and...
Key Takeaways
- Sun Pharma's profit falls on Organon deal charge; specialty drug sales remain strong Reuters Sun Pharma Q2 profit plunges 36% on exceptional charges despite revenue growth The Hindu Sun Pharma Q2 Results: PAT falls 36% to Rs 1,989 crore, misses estimates; revenue meets mark Zee Business How Is Sun Pharmaceutical Industries (NSE:SUNPHARMA) Balancing Innovation Spending and FY26 Growth?
- Kalkine India SUNPHARMA: Q2 sales growth was led by India and EM, offset by US Formulations pressure TradingView
- Full details and original dispatch available below.
Sun Pharma's profit falls on Organon deal charge; specialty drug sales remain strong Reuters Sun Pharma Q2 profit plunges 36% on exceptional charges despite revenue growth The Hindu Sun Pharma Q2 Results: PAT falls 36% to Rs 1,989 crore, misses estimates; revenue meets mark Zee Business How Is Sun Pharmaceutical Industries (NSE:SUNPHARMA) Balancing Innovation Spending and FY26 Growth? Kalkine India SUNPHARMA: Q2 sales growth was led by India and EM, offset by US Formulations pressure TradingView
Original Publisher Attribution
This summary was curated from Reuters.